BioCentury | Sep 2, 2020
Regulation

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

House oversight committee to subpoena AbbVie for pricing documents The U.S. House Committee on Oversight and Reform disclosed plans to issue a subpoena to AbbVie Inc. (NYSE:ABBV) for documents regarding pricing strategies for autoimmune drug...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...from the Phase IIb ZEST trial to treat atopic dermatitis. The pharma gained the oral HRH4...
...He was a venture partner at Brace Pharma Capital in 2016-18. Targets HRH4 (H4) - Histamine H4 receptor BioCentury...
BioCentury | Dec 4, 2019
Clinical News

Axsome plans Phase III trial for narcolepsy therapy following positive Phase II data

Axsome is readying for a Phase III trial next year of narcolepsy therapy AXS-12 after the candidate met the primary endpoint of a Phase II trial, sending the company's stock up $5.99 (15%) to $45.61...
BioCentury | Nov 6, 2019

Peptide inhibitors of a histone chaperone for osteosarcoma and breast cancer

...complexed with the histones H3 and H4 identified three residues on H3 and one on H4...
BioCentury | Aug 15, 2019
Company News

Harmony crosses finish line with Wakix for narcolepsy

FDA approved Wakix pitolisant Thursday, almost two years after Harmony gained U.S. rights to the narcolepsy drug. During 2017-18, Harmony raised $295 million to push it through registration. In October 2017, Harmony Biosciences LLC (Plymouth...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...choline Presbyopia Ph II Emricasan Pan-caspase protease inhibitor NASH Ph II First-in-indication ZPL389 Histamine H4 receptor (HRH4; H4...
BioCentury | May 20, 2019
Distillery Therapeutics

HIST4H4 inhibition to treat atherosclerosis

...include testing the mAb and peptide in pig models of atherosclerosis. TARGET/MARKER/PATHWAY: Histone cluster 4 H4...
...Maximilians University of Munich, Munich, Germany email: oliver.soehnlein@gmail.com Claire Quang Ludwig Maximilians University of Munich Histone cluster 4 H4...
BioCentury | Feb 27, 2019
Clinical News

Novartis first partner in RWE collaboration for dermatology

...that could benefit from the project: MOR106, an IL-17C targeted antibody; and ZPL-389, an oral HRH4...
...clinic for NASH, all of which are in Phase II testing. Targets: HRH4 (H4) - Histamine H4 receptor...
BioCentury | Aug 31, 2018
Company News

JW grants Leo rights to atopic dermatitis candidate JW1601

...between JW and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519). The compound is an oral histamine H4 receptor (HRH4; H4...
...Leo Pharma A/S, Ballerup, Denmark Business: Dermatology Jaime De Leon Chugai Pharmaceutical Co. Ltd. JW Pharmaceutical Corp. Leo Pharma A/S Histamine H4 receptor (HRH4) (H4) JW1601...
BioCentury | Mar 16, 2018
Clinical News

Glenmark's Ryaltris meets in Phase III for seasonal allergic rhinitis

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) reported data from a Phase III trial in 1,180 patients with seasonal allergic rhinitis showing that twice-daily Ryaltris mometasone/olopatadine met the primary endpoint of improving average morning and evening patient-reported...
Items per page:
1 - 10 of 123